RCUS FY2025 SEC EDGAR DEF 14A #143 of 168 in industry

Arcus Biosciences, Inc. CEO pay ratio

The CEO earned $2.4M in FY2025 against median worker pay of $269,269 · Chemicals & Pharmaceuticals.

Chemicals & Pharmaceuticals peers All rankings
State
DE
Filing date
2026-04-21
Industry
Chemicals & Pharmaceuticals
Industry rank
#143/168

Data updated August 2026

Subscribe to Arcus Biosciences, Inc. CEO pay filing updates (RSS)

CEO-to-worker pay ratio
9:1
Below Average (Scale: 0–1000:1)
CEO pay
$2.4M
Median worker
$269,269

Answer first

Arcus Biosciences, Inc.'s FY2025 CEO total of $2.4M ranks #1125 of 1,423 complete filings; its 9:1 pay ratio ranks #1289. Dollar rank is not ratio rank.

According to the same FY2025 complete-filing cohort used on the rankings boards (CEO total, median worker, and ratio all present). Median worker pay is $269,269. Industry placement uses the FY2025 SIC-28 peer cohort (# 143 of 168, 15th percentile - among the lower quartile of industry peers by pay ratio). Figures come from Section 953(b) Dodd-Frank DEF 14A disclosures - not estimates. View all Chemicals & Pharmaceuticals companies.

Dollar rank
#1125
$2.4M of 1,423 FY2025
Ratio rank
#1289
9:1 of 1,423
Industry pct
15th
among the lower quartile of industry peers by pay ratio

How Arcus Biosciences, Inc. ranks nationally

Arcus Biosciences, Inc. CEO pay vs. every FY2025 complete filing

Total CEO compensation, the full national distribution, this company marked

$2,423,421 21st percentile higher than 21% of 1,423 companies

$0–$2,500,000: 304 companies (21%). This entry sits in this band. $2,500,000–$5,000,000: 182 companies (13%). Above this entry. $5,000,000–$7,500,000: 208 companies (15%). Above this entry. $7,500,000–$10,000,000: 192 companies (13%). Above this entry. $10,000,000–$12,500,000: 139 companies (10%). Above this entry. $12,500,000–$15,000,000: 91 companies (6%). Above this entry. $15,000,000–$17,500,000: 88 companies (6%). Above this entry. $17,500,000–$20,000,000: 54 companies (4%). Above this entry. $20,000,000–$22,500,000: 24 companies (2%). Above this entry. $22,500,000–$25,000,000: 34 companies (2%). Above this entry. $25,000,000–$27,500,000: 24 companies (2%). Above this entry. $27,500,000–$30,000,000: 16 companies (1%). Above this entry. $30,000,000–$32,500,000: 10 companies (1%). Above this entry. $32,500,000–$35,000,000: 7 companies (0%). Above this entry. $35,000,000–$37,500,000: 9 companies (1%). Above this entry. $37,500,000–$40,000,000: 6 companies (0%). Above this entry. $40,000,000–$42,500,000: 1 companies (0%). Above this entry. $42,500,000–$45,000,000: 1 companies (0%). Above this entry. $45,000,000–$47,500,000: 6 companies (0%). Above this entry. $47,500,000–$50,000,000: 27 companies (2%). Above this entry. This company $0 $50M+ every complete-filing company, bucketed by value

Each bar is a $2500K-wide band; taller bars hold more companies. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source SEC DEF 14A Section 953(b) disclosures, PlainCEOPay extract · FY2025

Arcus Biosciences, Inc. vs. Chemicals & Pharmaceuticals peers

CEO total pay ($2.4M) against pay ratio (9:1) for Arcus Biosciences, Inc. (marked) and its 5 closest same-industry peers, against the Chemicals & Pharmaceuticals industry median on both axes.

Pay + gap both highContained pay, wide gapHigh pay, contained gapBelow peer norms on both02072365.44144730.96217096.38289461.86.3:115.7:125.0:134.4:143.7:1CEO total payPay ratio (CEO : median worker)Arcus Biosciences, Inc., CEO total pay: 2423421 · Pay ratio (CEO : median worker): 9:1Arcus Biosciences, Inc.Acadia Pharmaceuticals Inc, CEO total pay: 2574405 · Pay ratio (CEO : median worker): 9:1Acadia Pharmaceuticals IncAmylyx Pharmaceuticals, Inc., CEO total pay: 2685240 · Pay ratio (CEO : median worker): 9:1Amylyx Pharmaceuticals, Inc.Cumberland Pharmaceuticals Inc, CEO total pay: 101000 · Pay ratio (CEO : median worker): 10:1Cumberland Pharmaceuticals IncCollegium Pharmaceutical, Inc, CEO total pay: 1715846 · Pay ratio (CEO : median worker): 8:1Collegium Pharmaceutical, IncOmeros Corp, CEO total pay: 1533248 · Pay ratio (CEO : median worker): 8:1Omeros Corp
Arcus Biosciences, Inc. vs. Chemicals & Pharmaceuticals peers, plotted against the industry's $7.9M median CEO total and 42:1 median pay ratio.

Ratio bands among Chemicals & Pharmaceuticals peers

Exclusive CEO-to-median-worker bands across 153 complete latest-FY filings in SIC 28. Segments sum to the peer set, not this company's compensation pillar.

CEO Compensation Breakdown, FY2025

A component-level pay breakdown is not reported in Arcus Biosciences, Inc.'s structured SEC pay-ratio disclosure. See our methodology →

Filing-year trail · Arcus Biosciences, Inc.

Complete DEF 14A pay-ratio filings for this CIK across FY2021–2025. Year-over-year deltas compare adjacent filing years only; incomplete dollar rows are omitted (same completeness gate as the hero figures).

Latest ratio
9:1
FY2025
vs prior FY
0:1
from FY2024 9:1
CEO $ YoY
-67%
$2.4M latest
Filings shown
5
FY2021–2025
Arcus Biosciences, Inc. CEO total compensation, median worker pay, and pay ratio by fiscal year from SEC EDGAR DEF 14A.
FY CEO pay Δ pay Median worker Pay ratio Δ ratio
2021 $9.5M - $296,616 32:1 -
2022 $1.2M -87% $241,234 5:1 -27:1
2023 $10.1M +739% $1,686,824 6:1 +1:1
2024 $7.3M -28% $808,834 9:1 +3:1
2025 $2.4M -67% $269,269 9:1 0:1

Source: SEC EDGAR DEF 14A pay-ratio disclosures for CIK 1724521, FY2021–2025. Adjacent-year deltas only.

Industry Comparison - Chemicals & Pharmaceuticals

This Company's Ratio
9:1
Industry Median Ratio
42:1
Industry Median CEO Pay
$7.9M
This CEO's Pay
$2.4M
Companies in Industry
168
vs. Industry Median
Below
#143 of 168 by pay ratio in this industry View all companies in Chemicals & Pharmaceuticals →

Arcus Biosciences, Inc.: near-parity Item 402(u) ratio

Arcus Biosciences, Inc.'s FY2025 ratio 9:1 ranks #143 of 168 Chemicals & Pharmaceuticals filers (15th percentile). the CEO earned 9× the median employee ($269,269) in FY2025.

At $269,269 median worker pay, the FLOOR stamp is near pay-parity territory under MID$ CEO total.

CEO Total Pay

$2.4M

FY2025 Summary Compensation, below median

Pay Ratio

9:1

Below typical

Arcus Biosciences, Inc. in the lower Chemicals & Pharmaceuticals third

Arcus Biosciences, Inc.'s FY2025 ratio 9:1 ranks #143 of 168 Chemicals & Pharmaceuticals filers (15th percentile). The structured pay-ratio disclosure reports the total without line-item components. Chemicals & Pharmaceuticals (SIC 28) median ratio is 42:1 across 168 FY2025 filers; Arcus Biosciences, Inc.'s $2.4M CEO total is at or below the $7.9M industry median CEO pay.

Dollar rank #1125 and ratio rank #1289 split - treat 9:1 as a disclosure, not a fairness score. Open Chemicals & Pharmaceuticals peers.

Key Data, FY2025

Total Compensation
$2.4M
Median Employee Pay
$269,269
Pay Ratio
9:1
Filing Date
2026-04-21

Company Info

Ticker
RCUS
CIK
1724521
Industry
Chemicals & Pharmaceuticals
SIC Code
2834
State
DE
View SEC filings →
SEC EDGAR DEF 14A for CIK 1724521, FY2025. Informational only, not investment advice. Verify on EDGAR.

Read our methodology - how this data is sourced, computed, and verified. Arcus Biosciences, Inc.'s FY2025 ratio 9:1 ranks #143 of 168 Chemicals & Pharmaceuticals filers (15th percentile).

Read with Arcus Biosciences, Inc.

ABS(ceo_total_comp) peers first, then a SIC pole and a stamp-branched guide - not a fixed Related strip. This page stamps FLOOR · MID$ · ELITE-MED.

Community Healthcare Trust Inc · MID$

ABS(ceo_total_comp) peer at $2.4M (Δ $4K lighter vs Arcus Biosciences, Inc.); FLOOR · ELITE-MED vs this page's FLOOR · MID$ · ELITE-MED.
Jones Lang Lasalle Inc · MID$

ABS(ceo_total_comp) peer at $2.4M (Δ $7K heavier vs Arcus Biosciences, Inc.); STEEP · LOW-MED vs this page's FLOOR · MID$ · ELITE-MED.
National Presto Industries Inc · MID$

ABS(ceo_total_comp) peer at $2.4M (Δ $9K heavier vs Arcus Biosciences, Inc.); MODEST · PAR-MED vs this page's FLOOR · MID$ · ELITE-MED.
Spok Holdings, Inc · MID$

ABS(ceo_total_comp) peer at $2.4M (Δ $15K lighter vs Arcus Biosciences, Inc.); FLOOR · HIGH-MED vs this page's FLOOR · MID$ · ELITE-MED.
Acadia Pharmaceuticals Inc (SIC 28 pole)

Acadia Pharmaceuticals Inc stamps FLOOR · MID$ nearest in-SIC by ABS(pay_ratio) to Arcus Biosciences, Inc.'s FLOOR filing.
National dual ranks · #1125/#1289

Arcus Biosciences, Inc.'s FY2025 package sits #1125 by CEO dollars and #1289 by ratio under MID$ · FLOOR.
Ratio primer · FLOOR

Arcus Biosciences, Inc.'s FLOOR stamp sits in the lower Item 402(u) band - start with how the ratio is disclosed before comparing peers.
Data sourced from SEC EDGAR DEF 14A for Arcus Biosciences, Inc. (CIK 1724521), FY2025. See our methodology. Aggregated by PlainCEOPay as of August 2026.

Data currency: Executive compensation from SEC EDGAR DEF 14A proxy statements through fiscal year 2025, compiled and last refreshed August 2026. See our methodology for source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.